Key result
Norfloxacin at 400 mg bid did not significantly alter the pharmacokinetic parameters or anticoagulant effect of a single 30 mg dose of warfarin in healthy male subjects.
Why the study?
Does norfloxacin alter the disposition or anticoagulant effect of warfarin in healthy male subjects?
RCT (n=10)
randomized, crossover
Does norfloxacin alter the disposition or anticoagulant effect of warfarin in healthy male subjects?
Norfloxacin does not significantly alter the pharmacokinetics or anticoagulant effect of warfarin, suggesting a clinically important interaction is unlikely when co-administered.
No dose adjustment or extra monitoring needed with norfloxacin; confirms absence of interaction on warfarin PK/PD in healthy males.
Drug interactions related to inhibition of hepatic drug metabolism have been identified for some fluoroquinolone antibiotics. This study was designed to investigate whether the fluoroquinolone norfloxacin at the usual clinical dosage interacts with the anticoagulant agent warfarin. Ten healthy male subjects were administered a single oral dose of 30 mg warfarin sodium alone or during multiple-dose treatment with norfloxacin, 400 mg bid, in a randomized, crossover fashion. Plasma warfarin concentrations and prothrombin times were measured for 6 days after each of the two warfarin doses. The pharmacokinetic parameters of warfarin were comparable in the absence and presence of norfloxacin, including no significant differences in warfarin's elimination half-life, apparent total clearance, apparent volume of distribution, or peak plasma concentration. Norfloxacin also had no significant effect on the anticoagulant effect of warfarin, as assessed by the area under the prothrombin time versus time curve and the maximum response for prothrombin time. The lack of pharmacokinetic or pharmacodynamic interaction observed in this study suggests that a clinically important interaction of norfloxacin and warfarin is unlikely to occur in patients requiring both drugs.
No takes yet. Share an insight, caveat, or question.
Rocci et al. (1990) conducted an RCT in Healthy (n=10). Norfloxacin vs. Warfarin alone was evaluated on Pharmacokinetic parameters of warfarin and anticoagulant effect (prothrombin time). Norfloxacin at 400 mg bid did not significantly alter the pharmacokinetic parameters or anticoagulant effect of a single 30 mg dose of warfarin in healthy male subjects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: